Astria Therapeutics Target Price

Delisted . USA . 
Delisted Stock . Astria Therapeutics
ATXSDelisted Delisted Stock  USD 5,874  0.00  0.00%   
The Target Price for Astria Therapeutics is detailed below, including the formula and its most recent reported level. The displayed value tracks the most recently filed financial data.
=

13.0

Astria Therapeutics' Target Price is based on the most recent reporting period. Values may reflect either quarterly or annual reporting intervals.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Target Price Peer Comparison

Peer comparison on Target Price is one of the most widely used methods for evaluating Astria Therapeutics relative to competitors. Comparing Astria Therapeutics' Target Price against peers surfaces securities trading below their model-implied intrinsic value estimate in the group.
Astria Therapeutics is currently under evaluation in target price relative to competitors.

Important Fundamentals

Return On Equity TTM-0.43
Return On Asset TTM-0.27
Operating Margin TTM-48.31
Current Valuation590.19 M
Shares Outstanding57.08 M
Shares Owned By Insiders0.48 %
Shares Owned By Institutions94.90 %
Number Of Shares Shorted5.75 M
Price To Book TTM5.21 X
Price To Sales TTM1,017 X
Gross Profit TTM706 K
EBITDA TTM-111.56 M
Net Income TTM-94.26 M
Cash And Equivalents TTM102.48 M
Cash Per Share TTM7.87 X
Total Debt TTM5.35 M
Debt To Equity TTM0.01 %
Current Ratio TTM19.87 X
Book Value Per Share TTM2.44 X
Cash Flow From Operations TTM-81.21 M
Short Ratio TTM4.70 X
Earnings Per Share-2.14 X
Target Price13.0
Number Of Employees78
Trailing Beta0.019
Market Capitalization TTM718.13 M
Total Asset TTM342.36 M
Retained Earnings TTM-674.79 M
Working Capital TTM315.51 M
Net Asset342.36 M

Financial Metrics, Fundamentals & Methodology

Analyzing Astria Therapeutics means reviewing margin quality alongside capital risk exposure. The company is currently operating at a loss. Overall market capitalization tier is small-cap. In recent filings, Astria Therapeutics reported EPS loss of 2.14, negative operating margin of 48.31%, current ratio of 19.87 as of the latest reporting period.

Astria Therapeutics metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.